P01 AI131276 - 07/2017-06/2023 NCE - NIH/NIAID
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
MPI: Sallie Permar, MD, PhD, Weill Cornell Medicine
The goal is to define the origin, kinetics, and predictors of viral rebound in infants and to establish the impact on viral rebound of enhancing anti-viral humoral and T cell response via vaccination in order to guide development of new strategies to achieve pediatric HIV cure.
Role: Co-PI
UM1 AI164566 - 08/2021-04/2026- Johns Hopkins University via NIAID
Pediatric Adolescent Virus Eradiation (PAVE) Martin Delaney Collaboratory
MPI: Deborah Persaud, MD, Johns Hopkins
The overarching goal of this RF is to generate novel interventions for attaining ART-free control of pediatric HIV infection remission.
Role: Co-PI
R01 AI161008 - 09/2021-08/2026 - NIH/NIAID
Early life B cell responses and inflammation following SARS-CoV-2 infection
MPI: Genevieve Giny Fouda, MD, PhD (contact)
Major Goals: We propose to 1) characterize age-specific immune responses elicited by SARS-CoV-2; 2) define mechanisms driving protective immune responses; and 3) assess the relationship between virus- specific immune responses and symptomatic disease. We will use longitudinal samples from two unique previously enrolled household cohorts of SARS-CoV-2-infected children and adults.
Role: PI
R01 AI167850 - 04/2022-03/2027 – Duke University via NIAID
Impact of Early-life Exposure to Semi-Volatile Organic Compounds (SV)Cs) on Neonatal and Early Childhood Immune Function
MPI: Kate Hoffman, PhD, Duke University
Major Goals: The overall goal of this study is to assess the development of HIV-specific antibody responses in young children.
Role: PI Subaward
R01 AI143370-04 - 03/2019-02/2024 - NIH/NIAID
Neutralizing and non-neutralizing antibody effector functions in HIV infected children
MPI: Genevieve Giny Fouda
The overall goal of this study is to assess the development of HIV-specific antibody responses in young children.
Role: PI
R01 AI145016 - 04/2019-03/2023 - Duke University via NIAID
Supramolecular pediatric HIV vaccine design
MPI: Joel Collier, Duke University
The goal of this project is to develop an innovative nanofiber pediatric HIV vaccine comprised of a scaffolded CH505 SOSIP Env trimer and a synthetic T-Cell epitope (PADRE) self-assembled into supramolecular nanofibers and to test if the PADRE- HIV-1 Env trimer vaccine enhances the magnitude and potency of tier 2 virus neutralization responses in small animal and infant primate models.
Role: PI, Subaward